OM DETTA AVSNITT
In this episode of the IDEA Collider podcast, industry experts explore the evolving role of AI in Competitive Intelligence (CI) in pharmaceutical and biotech strategy — and how organizations can move beyond data collection to drive smarter, more confident decision-making.
Featuring insights from Erik Nordhoy, CEO of SAI MedPartners, alongside his team, John Barry, Matt Boucher, Jennifer Preston, and Lucia Fernandez Barreiros, this conversation examines how cross-functional teams can interpret insights, manage uncertainty, and improve portfolio outcomes in complex drug development environments. The discussion covers artificial intelligence, asymmetric learning, forecasting challenges, strategic alignment, and the leadership mindset required to navigate innovation in biopharma.
SAI MedPartners is a global consultancy that provides strategic insights, competitive intelligence, market research, and commercialization strategy to pharmaceutical, biotechnology, and medical device companies across the product lifecycle. This episode is a must-listen for leaders working across drug development, commercialization strategy, and pharmaceutical innovation.
Keep up with the guests;
Erik Nordhoy - President at SAI MedPartners LLC https://www.linkedin.com/in/erik-nordhoy-6996241/
John Barry - Executive Vice President at SAI MedPartners LLC https://www.linkedin.com/in/johnnbarry/
Matt Boucher, PhD - Director, Oncology BU, SAI MedPartners LLC https://www.linkedin.com/in/matthewbchr/
Jennifer Preston - VP, Artificial Intelligence Leader, SAI MedPartners LLC https://www.linkedin.com/in/jennifer-j-preston/
Lucia Fernandez Barreiros - Consulting Analyst, SAI MedPartners LLC https://www.linkedin.com/in/lucia-fernandez-barreiros-ba5260224/
Follow Mike Rea On;
Website: https://ideacollider.simplecast.com/
X: https://x.com/ideapharma
LinkedIn: https://www.linkedin.com/in/bigidea/
Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/
